Back to top
more

Amgen (AMGN)

(Real Time Quote from BATS)

$325.84 USD

325.84
661,677

+3.93 (1.22%)

Updated Nov 8, 2024 01:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Biogen Alzheimer's Drug Aducanumab Gets Rejected by FDA Panel

by Zacks Equity Research

If Biogen's (BIIB) aducanumab is approved by the FDA going forward, it will become the first medicine to be approved to reduce the clinical decline associated with Alzheimer's disease.

Sweta Jaiswal, FRM headshot

How Will Biotech ETFs React to These Q3 Earnings Release?

by Sweta Jaiswal, FRM

Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their third-quarter earnings releases amid the coronavirus crisis.

Biotech Stock Roundup: Gilead, Amgen, Vertex and Alexion Report Q3 Earnings & More

by Zacks Equity Research

Third-quarter earnings take centerstage in the biotech sector as Gilead (GILD), Amgen (AMGN) and others report results.

Ligand (LGND) Q3 Earnings & Sales Fall Short of Estimates

by Zacks Equity Research

Ligand (LGND) reports lower-than-expected third-quarter 2020 earnings and revenues. Outlook for 2020 & 2021 also are below expectations. Stock down.

AbbVie (ABBV) Beats on Q3 Earnings & Sales, Ups 2020 Guidance

by Zacks Equity Research

AbbVie (ABBV) beats on third-quarter 2020 earnings and revenues. Shares up in pre-market trading.

Amgen (AMGN) Q3 Earnings Top, Prolia, Biosimilars Drive Sales

by Zacks Equity Research

Amgen (AMGN) beats Q3 estimates for both earnings and sales. It slightly narrows its previously issued sales guidance for 2020 while raising its earnings range.

Amgen (AMGN) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Amgen (AMGN) delivered earnings and revenue surprises of 16.53% and 0.65%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

What's in Store for Ligand (LGND) This Earnings Season?

by Zacks Equity Research

Higher Captisol sales to support availability of Gilead's COVID-19 treatment, remdisivir, is expected to have driven Ligand's (LGND) revenues in the third quarter.

    Biotech Stock Roundup: GILD's Veklury Approved, NVAX Provides Vaccine Update & More

    by Zacks Equity Research

    Gilead (GILD) and Novavax (NVAX) continue to be in the spotlight on coronavirus-related updates.

    Drug/Biotech Stock Q3 Earnings on Oct 28: GSK, AMGN & More

    by Zacks Equity Research

    Let us take a look at four drug/biotech companies due to release their quarterly results on Oct 28.

    The Zacks Analyst Blog Highlights: Pfizer, Merck & Co., Bristol-Myers Squibb and Amgen

    by Zacks Equity Research

    The Zacks Analyst Blog Highlights: Pfizer, Merck & Co., Bristol-Myers Squibb and Amgen

    Pfizer (PFE) Q3 Earnings Top, Sales Miss, View Narrowed

    by Zacks Equity Research

    Pfizer (PFE) beats estimates for earnings while missing the same for sales. It narrows its financial outlook for the year.

    Will Pfizer's (PFE) Oncology Drugs Drive Its Q3 Earnings?

    by Zacks Equity Research

    In Pfizer's (PFE) Biopharma unit, oncology sales are likely to have risen in the third quarter, while in non-oncology, Eliquis alliance revenues are likely to have supported the top line.

    Sweta Killa headshot

    Healthcare to Post Solid Q3 Earnings Growth: ETFs in Focus

    by Sweta Killa

    The healthcare is expected to witness substantial earnings growth of 5.1% in the third quarter, representing the second strongest sector this earnings season.

    Amgen (AMGN) to Report Q3 Earnings: What's in the Cards?

    by Zacks Equity Research

    Investors will focus on whether Amgen's (AMGN) sales have recovered in the third quarter from the COVID-19 effect.

    Centene (CNC) to Report Q3 Earnings: What's in the Cards?

    by Zacks Equity Research

    Centene's (CNC) Q3 results are likely to reflect benefits from growing revenues and improving membership.

    Alexion (ALXN) to Report Q3 Earnings: What's in the Cards?

    by Zacks Equity Research

    Alexion (ALXN) will provide updates on its marketed drugs, earnings and other pipeline candidates when it releases third-quarter 2020 results on Oct 29.

    Sweta Killa headshot

    Healthcare to Post Solid Q3 Earnings Growth: ETFs in Focus

    by Sweta Killa

    The healthcare is expected to witness substantial earnings growth of 5.1% in the third quarter, representing the second strongest sector this earnings season.

    Amgen (AMGN) Reports Next Week: Wall Street Expects Earnings Growth

    by Zacks Equity Research

    Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    AbbVie (ABBV) Files for Rinvoq in Atopic Dermatitis in US & EU

    by Zacks Equity Research

    AbbVie (ABBV) files regulatory applications with the FDA and the EMA, seeking approval for a new indication of Rinvoq ??? atopic dermatitis. The drug is already marketed to treat rheumatoid arthritis.

    Merck's Keytruda Gets FDA Nod for Expanded Use in Lymphoma

    by Zacks Equity Research

    The FDA approves Merck's (MRK) Keytruda for the treatment of adult patients with relapsed or refractory cHL who progress after frontline therapy.

    Sheraz Mian headshot

    Top Research Reports for Novartis, Zoom Video & FIS

    by Sheraz Mian

    Today's Research Daily features new research reports on 16 major stocks, including Novartis (NVS), Zoom Video Communications (ZM) and Fidelity National Information Services (FIS).

    Biotech Stock Roundup: REGN, GILD's Coronavirus News & Other Pipeline Updates

    by Zacks Equity Research

    Regeneron (REGN) and Gilead (GILD) continue to be in the spotlight on coronavirus-related updates.

    Amgen Down on Unsatisfactory Heart Failure Drug Study Results

    by Zacks Equity Research

    Amgen (AMGN) with partners post top-line data from the phase III GALACTIC-HF study on omecamtiv mecarbil, which is being evaluated for heart failure with reduced ejection fraction. Stock falls.

    Signs That Your Trading Will Ruin Your Retirement - October 08, 2020

    by Zacks Equity Research

    Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.